retatrutide triple hormone receptor agonist metabolic for dysfunction-associated steatotic liver disease: a randomized phase 2a trial 🧬 R3TA is a next-generation

The expanded regulatory approvals for chronic weight management and cardiovascular risk reduction are a few of the key factors driving market growth

The study in isolated human atrial preparations demonstrated that retatrutide increases the rate of tension development and the peak tension of cardiac contractions

Why These Three Work Together Retatrutide, Tesamorelin, and MOTS-C target different pathways that compound on each other: Retatrutide is a triple-agonist GLP-1/GIP/glucagon receptor agonist

This highlights the importance of M&A for these emerging therapeutics in an investment thesis, as such trials are much more feasible for large pharma companies than for biotech startups